HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
Halozyme Therapeutics (HALO) Tops Q4 EPS by 1c
February 22, 2022 4:02 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.42, $0.01 better than the analyst estimate of $0.41. Revenue for the quarter came in at $102 million versus the consensus estimate of $100.29 million.
GUIDANCE:
Halozyme Therapeutics sees FY2022 EPS of $2.05-$2.20, versus the consensus of $2.18.... More
